Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...

Following his medical training in Pathology and Rheumatology at the National University ... and genetic players leading to murine lupus nephritis, with corresponding translational studies in human ...

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

in collaboration with Nizam’s Institute of Medical Sciences (NIMS), Hyderabad has unveiled publicly available datasets comprising digitized histopathological images of brain cancer and kidney disease ...

Hyderabad: IIIT Hyderabad, in collaboration with Nizam's Institute of Medical Sciences (NIMS), has released digitised datasets of histopathological images focused on brain cancer and kidney disease ...

These datasets include high-resolution images of brain cancer and kidney disease (Lupus Nephritis), forming the cornerstone of the India Pathology Dataset (IPD) project. Histopathological images ...